EPID-07. HEMATOLOGICAL ADVERSE EVENTS IN GLIOBLASTOMA PATIENTS TREATED WITH TEMOZOLOMIDE

BACKGROUND: Temozolomide (TMZ) is the cornerstone for glioblastoma (GBM) treatment. A significant proportion of patients develops hematologic toxicities with limited investigations on outcomes and risk factors for their development. METHODS: Our study combines data from the two largest group trials,...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Neuro Oncol
Auteurs principaux: Garcia, Catherine, Myint, Zin, Jayswal, Rani, Butts, Allison, Weiss, Heidi, Villano, John
Format: Artigo
Langue:Inglês
Publié: Oxford University Press 2019
Sujets:
Epidemiology
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6846982/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.307
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires